Head and Neck Cancer-Taxotere Approved

by Medindia Content Team on  October 19, 2006 at 1:14 PM Cancer News
RSS Email Print This Page Comment
Head and Neck Cancer-Taxotere Approved
Taxotere(docetaxel) from Sanofi-Aventis has been approved for its treatment by the FDA, following a clinical trial. The study showed that patients given chemotherapy with Taxotere survived an average of 11.4 months without disease progression, as compared to 8.3 months with standard drugs.
Advertisement

The drug will be used before radiation, in combination with cisplatin and fluorouracil chemotherapy in locally advanced squamous cell head and neck cancer. Its side effects are nausea, mouth ulcers, hair loss and depletion of blood cells.

Advertisement
The drug is already in use for treating breast cancer, non small cell lung cancer and prostate cancer and is now approved for treating inoperable types of head and neck cancer.Taxotere was last year's third best selling drug for Sanofi and its sales are likely to rise further following the approval.

Source: Medindia
MAL
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive